Fresh analysis reveals that individuals who come off blockbuster slimming jabs like semaglutide or tirzepatide may regain lost weight much more quickly than those who halt conventional diet and exercise regimens.
Findings released in a leading medical journal demonstrates that while obese individuals often shed a large proportion of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Individuals purchasing such treatments must be cognizant of the danger of rapid rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb.
Such speed of recovery implies a reversion to pre-treatment weight in about a year and a half.
Analyzing Approaches
The analysis, which examined 37 of studies involving over 9,000 of participants, compared the effects of the injectable medications with conventional dieting.
The team note that people who shed pounds through diet and exercise typically experience a more gradual weight regain—approximately 0.1 kg a month—after stopping.
Explaining the Rapid Rebound
Nutrition scientists believe the mode of action of the injections accounts for the amplified weight return.
GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate hunger.
"Sustained high doses of GLP-1 levels several times higher than normal might result in the system to produce less of its endogenous hormone, and could reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication results in hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Issue?
The NHS recommend the jabs for individuals with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, given the significant potential of weight regain, the treatment might need to be ongoing.
This perspective is reinforced by drug manufacturers, who state that the results "emphasize the chronic nature of obesity," akin to managing conditions like diabetes.
Patient Experiences
Users who have discontinued the medication explain a sudden resurgence of appetite.
"It was like a switch that goes on and you become extremely hungry," said one woman.
This difficulty is worsened if patients have not established sustainable lifestyle or habit modifications during therapy.
Growing Interest
Recent estimates suggest that a significant number of people in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Use is higher among females than men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
In conclusion, researchers stress that while these medications are effective agents for weight loss, they are not a standalone cure and long-term success hinges on integrated lifestyle management.
